{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T12:52:42Z","timestamp":1784983962943,"version":"3.55.0"},"reference-count":104,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T00:00:00Z","timestamp":1459468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","lungcancerjournal.info","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1016\/j.lungcan.2016.01.010","type":"journal-article","created":{"date-parts":[[2016,1,21]],"date-time":"2016-01-21T14:12:04Z","timestamp":1453385524000},"page":"7-14","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":48,"special_numbering":"C","title":["The role of new PET tracers for lung cancer"],"prefix":"10.1016","volume":"94","author":[{"given":"Teresa A.","family":"Szyszko","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Connie","family":"Yip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Szlosarek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicky","family":"Goh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary J.R.","family":"Cook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2016.01.010_bib0005","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1159\/000092080","article-title":"The future in diagnosis and staging of lung cancer: positron emission tomography","volume":"73","author":"Fischer","year":"2006","journal-title":"Respiration"},{"key":"10.1016\/j.lungcan.2016.01.010_bib0010","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1056\/NEJM200007273430404","article-title":"Preoperative staging of nonsmall-cell lung cancer with positron-emission tomography","volume":"343","author":"Pieterman","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2016.01.010_bib0015","doi-asserted-by":"crossref","first-page":"88","DOI":"10.2967\/jnumed.108.054205","article-title":"18F-FDG PET and PET\/CT in the evaluation of cancer treatment response","volume":"50","author":"Ben-Haim","year":"2009","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.lungcan.2016.01.010_bib0020","first-page":"1426","article-title":"Imaging proliferation in lung tumors with PET:18F-FLT versus 18F-FDG","volume":"44","author":"Buck","year":"2003","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.lungcan.2016.01.010_bib0025","first-page":"1596","article-title":"18F-FDG PET provides high-impact and powerful prognostic stratification in staging newly diagnosed non-small cell lung cancer","volume":"42","author":"Hicks","year":"2001","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.lungcan.2016.01.010_bib0030","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1200\/JCO.2001.19.1.111","article-title":"Clinical impact of (18)F fluorodeoxyglucose positron emission tomography in patients with non-small-cell lung cancer: a prospective study","volume":"19","author":"Kalff","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2016.01.010_bib0035","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1001\/jama.285.7.914","article-title":"Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions: a meta-analysis","volume":"285","author":"Gould","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.lungcan.2016.01.010_bib0040","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1148\/radiographics.19.1.g99ja0761","article-title":"Pitfalls in oncologic diagnosis with FDG PET imaging: physiologic and benign variants","volume":"19","author":"Shreve","year":"1999","journal-title":"Radiographics"},{"key":"10.1016\/j.lungcan.2016.01.010_bib0045","first-page":"104","article-title":"Microautoradiographic study for the differentiation of intratumoral macrophages: granulation tissues and cancer cells by the dynamics of fluorine-18-fluorodeoxyglucoseuptake","volume":"35","author":"Kubota","year":"1994","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.lungcan.2016.01.010_bib0050","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0169-5002(00)00250-6","article-title":"Correlation of FDG-PET imaging withGlut-1 and Glut-3 expression in early-stage non-small cell lung cancer","volume":"33","author":"Marom","year":"2001","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2016.01.010_bib0055","first-page":"556","article-title":"Glucose transporters and FDG uptake in untreated human non-small cell lung cancer","volume":"40","author":"Brown","year":"1999","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.lungcan.2016.01.010_bib0060","first-page":"2118","article-title":"Tracer feasibility for monitoring tumor radiotherapy: a quadruple tracer study with fluorine-18-fluorodeoxyglucose or fluorine-18-fluorodeoxyuridine L-[methyl-14C]methionine, [6-3H]thymidine, and gallium-67","volume":"32","author":"Kubota","year":"1991","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.lungcan.2016.01.010_bib0065","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1200\/JCO.20.2.379","article-title":"Biologic correlates of (18) fluoro-deoxyglucose uptake in human breast cancer measured by positron emission tomography","volume":"20","author":"Bos","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2016.01.010_bib0070","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/S1556-0864(15)31531-8","article-title":"Prognostic value of fluorodeoxyglucose positron emission tomography in non-small cell lung cancer: a review","volume":"1","author":"Pillot","year":"2006","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2016.01.010_bib0075","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1097\/JTO.0b013e318160c122","article-title":"Prognostic value of preoperative positron emission tomography in resected stage I non-small cell lung cancer","volume":"3","author":"Goodgame","year":"2008","journal-title":"J. Thorac. Oncol."},{"issue":"8","key":"10.1016\/j.lungcan.2016.01.010_bib0080","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1002\/cncr.22979","article-title":"Predictive and prognostic value of FDG-PET in nonsmall-cell lung cancer: a systematic review","volume":"110","author":"de Geus-Oei","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.lungcan.2016.01.010_bib0085","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.1200\/JCO.2003.12.004","article-title":"Positron emission tomography in nonsmall-cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use","volume":"21","author":"Weber","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2016.01.010_bib0090","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1016\/j.athoracsur.2004.06.102","article-title":"Repeat 18F-FDGPETafter neoadjuvant therapy is a predictor of pathologic response in patients with non-small cell lung cancer","volume":"78","author":"Cerfolio","year":"2004","journal-title":"Ann. Thorac. Surg."},{"key":"10.1016\/j.lungcan.2016.01.010_bib0095","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1038\/3337","article-title":"Imaging proliferation in vivo with [18F]FLT and positron emission tomography","volume":"4","author":"Shields","year":"1998","journal-title":"Nat. Med."},{"issue":"3","key":"10.1016\/j.lungcan.2016.01.010_bib0100","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s00259-004-1611-0","article-title":"The uptake of 3\u2032-deoxy-3\u2032-18F]fluorothymidine into L178Y tumours in vivo is dependent on thymidine kinase 1 protein levels","volume":"32","author":"Barthel","year":"2005","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.lungcan.2016.01.010_bib0105","first-page":"1210","article-title":"Validation of FLT uptake as a measure of thymidine kinase-1 activity in A549 carcinoma cells","volume":"43","author":"Rasey","year":"2002","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.lungcan.2016.01.010_bib0110","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s11307-006-0039-2","article-title":"Positron emission tomography measurement of tumor metabolism and growth: its expanding role in oncology","volume":"8","author":"Shields","year":"2006","journal-title":"Mol. Imaging Biol."},{"key":"10.1016\/j.lungcan.2016.01.010_bib0115","first-page":"331","article-title":"3-Deoxy-3-[18F]fluorothymidine-positron emission tomography for noninvasive assessment of proliferation in pulmonary nodules","volume":"62","author":"Buck","year":"2002","journal-title":"Cancer Res."},{"issue":"4","key":"10.1016\/j.lungcan.2016.01.010_bib0120","doi-asserted-by":"crossref","first-page":"528","DOI":"10.2967\/jnumed.109.072124","article-title":"Measuring tumor cell proliferation with 18F-FLT PET during radiotherapy of esophageal squamous cell carcinoma: a pilot clinical study","volume":"51","author":"Yue","year":"2010","journal-title":"J. Nucl. Med."},{"issue":"5","key":"10.1016\/j.lungcan.2016.01.010_bib0125","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/s00259-004-1706-7","article-title":"Clinical relevance of imaging proliferative activity in lung nodules","volume":"32","author":"Buck","year":"2005","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.lungcan.2016.01.010_bib0130","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1007\/s00259-010-1412-6","article-title":"Imaging of proliferation with 18F-FLT PET\/CT versus 18F-FDG PET\/CT in non-small-cell lung cancer","volume":"37","author":"Yang","year":"2010","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"2","key":"10.1016\/j.lungcan.2016.01.010_bib0135","doi-asserted-by":"crossref","first-page":"186","DOI":"10.2967\/jnumed.107.044966","article-title":"A multicenter clinical trial on the diagnostic value of dual-tracer PET\/CT in pulmonary lesions using 3'-deoxy-3'-18F-fluorothymidine and 18F-FDG","volume":"49","author":"Tian","year":"2008","journal-title":"J. Nucl. Med."},{"issue":"22","key":"10.1016\/j.lungcan.2016.01.010_bib0140","doi-asserted-by":"crossref","first-page":"7423","DOI":"10.1158\/1078-0432.CCR-08-0312","article-title":"[18F]Fluorothymidine positron emission tomography before and 7days after gefitinib treatment predicts response in patients with advanced adenocarcinoma of the lung","volume":"14","author":"Sohn","year":"2008","journal-title":"Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.lungcan.2016.01.010_bib0145","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1007\/s00259-013-2632-3","article-title":"Early reduction in tumour [18F]fluorothymidine (FLT) uptake in patients with non-small cell lung cancer (NSCLC) treated with radiotherapy alone","volume":"41","author":"Trigonis","year":"2014","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"7","key":"10.1016\/j.lungcan.2016.01.010_bib0150","doi-asserted-by":"crossref","first-page":"e111","DOI":"10.1200\/JCO.2012.42.1784","article-title":"Metabolic response to pegylated arginine deiminase in mesothelioma with promotermethylation of argininosuccinate synthetase","volume":"31","author":"Szlosarek","year":"2013","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.lungcan.2016.01.010_bib0155","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1158\/0008-5472.CAN-13-1702","article-title":"Prognostic and therapeutic impact of argininosuccinate synthetase 1 control in bladder cancer as monitored longitudinally by PET imaging","volume":"74","author":"Allen","year":"2014","journal-title":"Cancer Res."},{"key":"10.1016\/j.lungcan.2016.01.010_bib0160","doi-asserted-by":"crossref","first-page":"498","DOI":"10.3171\/jns.2005.103.3.0498","article-title":"Usefulness of L-[methyl-11C] methionine-positron emission tomography as a biological monitoring tool in the treatment of glioma","volume":"103","author":"Nariai","year":"2005","journal-title":"J. Neurosurg."},{"issue":"8","key":"10.1016\/j.lungcan.2016.01.010_bib0165","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.2967\/jnumed.112.103069","article-title":"Transport of 3-fluoro-L-\u03b1-methyl-tyrosine by tumor-upregulated L-type amino acid transporter 1: a cause of the tumor uptake in PET","volume":"53","author":"Wiriyasermkul","year":"2012","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.lungcan.2016.01.010_bib0170","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1148\/radiol.2351041662","article-title":"CT screening for lung cancer: five-year prospective experience","volume":"235","author":"Swensen","year":"2005","journal-title":"Radiology"},{"key":"10.1016\/j.lungcan.2016.01.010_bib0175","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1007\/BF00253516","article-title":"Tumor detection with carbon-11-labelled amino acids","volume":"9","author":"Kubota","year":"1984","journal-title":"Eur. J. Nucl. Med."},{"key":"10.1016\/j.lungcan.2016.01.010_bib0180","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/s12149-007-0142-8","article-title":"The feasibility of 11C-methionine-PET in diagnosis of solitary lung nodules\/masses when compared with 18F-FDG-PET","volume":"22","author":"Hsieh","year":"2008","journal-title":"Ann. Nucl. Med."},{"key":"10.1016\/j.lungcan.2016.01.010_bib0185","series-title":"Basic Clinical Radiobiology","first-page":"207","article-title":"The oxygen effect and fractionated radiotherapy","author":"Horsman","year":"2009"},{"key":"10.1016\/j.lungcan.2016.01.010_bib0190","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1259\/0007-1285-26-312-638","article-title":"The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy","volume":"26","author":"Gray","year":"1953","journal-title":"Br. J. Radiol."},{"key":"10.1016\/j.lungcan.2016.01.010_bib0195","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s10555-007-9055-1","article-title":"Hypoxia in cancer: significance and impact on clinical outcome","volume":"26","author":"Vaupel","year":"2007","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.lungcan.2016.01.010_bib0200","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1006\/gyno.1993.1262","article-title":"Tumor oxygenation: a new predictive parameter in locally advancedcancer of the uterine cervix","volume":"51","author":"Hockel","year":"1993","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.lungcan.2016.01.010_bib0205","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0167-8140(96)01811-7","article-title":"Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck","volume":"41","author":"Nordsmark","year":"1996","journal-title":"Radiother. Oncol."},{"key":"10.1016\/j.lungcan.2016.01.010_bib0210","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1007\/BF03038495","article-title":"Survival of exclusively irradiated patients with NSCLC. Significance of pretherapeutic hemoglobin level","volume":"174","author":"Wilhelm","year":"1998","journal-title":"StrahlentherOnkol."},{"key":"10.1016\/j.lungcan.2016.01.010_bib0215","doi-asserted-by":"crossref","first-page":"292","DOI":"10.2307\/3576986","article-title":"Characterization of radiolabeled fluoromisonidazole as a probe for hypoxic cells","volume":"111","author":"Rasey","year":"1987","journal-title":"Radiat. Res."},{"key":"10.1016\/j.lungcan.2016.01.010_bib0220","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1007\/s00259-005-1880-2","article-title":"Utility of FMISO PET in advanced head and neck cancer treated with chemoradiation incorporating a hypoxia-targeting chemotherapy agent","volume":"32","author":"Hicks","year":"2005","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.lungcan.2016.01.010_bib0225","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1007\/s00259-002-1096-7","article-title":"[(18)F]FMISO and [(18)F]FDG PET imaging in soft tissue sarcomas: correlation of hypoxia: metabolism and VEGF expression","volume":"30","author":"Rajendran","year":"2003","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.lungcan.2016.01.010_bib0230","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1016\/0006-2952(91)90245-Z","article-title":"Reduction of fluoromisonidazole: a new imaging agent for hypoxia","volume":"42","author":"Prekeges","year":"1991","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.lungcan.2016.01.010_bib0235","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1053\/j.semnuclmed.2007.07.001","article-title":"Hypoxia positron emission tomography imaging with 18F-fluoromisonidazole","volume":"37","author":"Lee","year":"2007","journal-title":"Semin. Nucl. Med."},{"key":"10.1016\/j.lungcan.2016.01.010_bib0240","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1007\/s00259-015-3009-6","article-title":"Molecular imaging of hypoxia in non-small-cell lung cancer","volume":"42","author":"Yip","year":"2015","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.lungcan.2016.01.010_bib0245","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1007\/s00259-010-1569-z","article-title":"Molecular imaging in cancer treatment","volume":"38","author":"Michalski","year":"2011","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.lungcan.2016.01.010_bib0250","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.ijrobp.2014.09.045","article-title":"A comparative study of the hypoxia PET tracers [(18)F]HX4 [(18)F]FAZA, and [(18)F]FMISO in a preclinical tumor model","volume":"91","author":"Peeters","year":"2015","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.lungcan.2016.01.010_bib0255","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/0360-3016(95)00170-4","article-title":"Evaluation of oxygenation status during fractionated radiotherapy in human non small cell lung cancers using [F-18]fluoromisonidazole positron emission tomography","volume":"33","author":"Koh","year":"1995","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.lungcan.2016.01.010_bib0260","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0360-3016(92)91001-4","article-title":"Imaging of hypoxia in human tumors with [F-18]fluoromisonidazole","volume":"22","author":"Koh","year":"1992","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.lungcan.2016.01.010_bib0265","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S0360-3016(96)00325-2","article-title":"Quantifying regional hypoxia in human tumors with positron emission tomography of [18F]fluoromisonidazole: a pretherapy study of 37 patients","volume":"36","author":"Rasey","year":"1996","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.lungcan.2016.01.010_bib0270","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/1471-2407-6-51","article-title":"[18F]fluoromisonidazole and [18F]fluorodeoxyglucose positronemission tomography in response evaluation after chemo-\/radiotherapy of non-small-cell lung cancer: a feasibility study","volume":"6","author":"Gagel","year":"2006","journal-title":"BMC Cancer."},{"key":"10.1016\/j.lungcan.2016.01.010_bib0275","first-page":"253","article-title":"Prognostic impact of hypoxia imaging with 18Fmisonidazole PET in non-small cell lung cancer and head and neck cancer before radiotherapy","volume":"46","author":"Eschmann","year":"2005","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.lungcan.2016.01.010_bib0280","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.radonc.2010.10.011","volume":"98","author":"Vera","year":"2011","journal-title":"Radiother. Oncol."},{"key":"10.1016\/j.lungcan.2016.01.010_bib0285","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/S0969-8051(02)00442-0","article-title":"[18F]Fluoroazomycinarabinofuranoside (18FAZA) and [18F]Fluoromisonidazole 18FMISO): a comparative study of their selective uptake in hypoxic cells and PET imaging in experimental rat tumors","volume":"30","author":"Sorger","year":"2003","journal-title":"Nucl. Med. Biol."},{"key":"10.1016\/j.lungcan.2016.01.010_bib0290","first-page":"106","article-title":"Hypoxia-specific tumor imaging with 18F-fluoroazomycin arabinoside","volume":"46","author":"Piert","year":"2005","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.lungcan.2016.01.010_bib0295","doi-asserted-by":"crossref","first-page":"90","DOI":"10.5603\/NMR.2011.00022","article-title":"Contribution of [64Cu]-ATSM PET in molecular imaging of tumour hypoxia compared to classical [18F]-MISO\u2014a selected review","volume":"14","author":"Bourgeois","year":"2011","journal-title":"Nucl. Med. Rev. Cent East Eur."},{"key":"10.1016\/j.lungcan.2016.01.010_bib0300","doi-asserted-by":"crossref","first-page":"S117","DOI":"10.1102\/1470-7330.2007.0001","article-title":"PET imaging of tumour hypoxia","volume":"6","author":"Padhani","year":"2006","journal-title":"Cancer Imaging"},{"key":"10.1016\/j.lungcan.2016.01.010_bib0305","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/S0360-3016(02)04477-2","article-title":"Assessing tumor hypoxia in cervical cancer by positron emission tomography with 60Cu-ATSM: relationship to therapeutic response\u2014a preliminary report","volume":"55","author":"Dehdashti","year":"2003","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.lungcan.2016.01.010_bib0310","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1007\/s00259-003-1130-4","article-title":"In vivo assessment of tumor hypoxia in lung cancer with 60Cu-ATSM","volume":"30","author":"Dehdashti","year":"2003","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.lungcan.2016.01.010_bib0315","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.2967\/jnumed.109.069021","article-title":"Pathophysiologic correlation between 62Cu-ATSM and 18FFDG in lung cancer","volume":"50","author":"Lohith","year":"2009","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.lungcan.2016.01.010_bib0320","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.nucmedbio.2009.01.016","article-title":"Radio-copper-labeled Cu-ATSM: an indicator of quiescent but clonogenic cells under mild hypoxia in a Lewis lung carcinoma model","volume":"36","author":"Oh","year":"2009","journal-title":"Nucl. Med. Biol."},{"key":"10.1016\/j.lungcan.2016.01.010_bib0325","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1007\/s00259-003-1130-4","article-title":"In vivo assessment of tumor hypoxia in lung cancer with 60Cu-ATSM","volume":"30","author":"Dehdashti","year":"2003","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"1","key":"10.1016\/j.lungcan.2016.01.010_bib0330","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.cpet.2009.04.011","article-title":"PET imaging of Angiogenesis","volume":"4","author":"Niu","year":"2009","journal-title":"PET Clin."},{"key":"10.1016\/j.lungcan.2016.01.010_bib0335","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1007\/s00330-011-2311-3","article-title":"Experimental Cancer Medicine Centre 13 Imaging Network Group: recommendations for measurement of tumour vascularity with positron emission tomography in early phase clinical trials","volume":"22","author":"Aboagye","year":"2012","journal-title":"Eur. Radiol."},{"key":"10.1016\/j.lungcan.2016.01.010_bib0340","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1021\/bc0155566","article-title":"In vitro and in vivo evaluation of a technetium-99m-labeled cyclic RGD peptide as a specific marker of alpha(V) beta(3) integrin for tumor imaging","volume":"13","author":"Su","year":"2002","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.lungcan.2016.01.010_bib0345","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1034\/j.1399-3011.1999.00055.x","article-title":"The effect of conformation on the solution stability of linear vs cyclic RGD peptides","volume":"53","author":"Bogdanowich-Knipp","year":"1999","journal-title":"J. Pept. Res."},{"issue":"suppl. 1","key":"10.1016\/j.lungcan.2016.01.010_bib0350","doi-asserted-by":"crossref","first-page":"S104","DOI":"10.1007\/s00259-010-1499-9","article-title":"Molecular imaging of angiogenesis with SPECT","volume":"37","author":"Dijkgraaf","year":"2010","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.lungcan.2016.01.010_bib0355","doi-asserted-by":"crossref","first-page":"48","DOI":"10.7150\/thno\/v01p0048","article-title":"PET imaging of integrin alphaVbeta3 expression","volume":"1","author":"Beer","year":"2011","journal-title":"Theranostics"},{"key":"10.1016\/j.lungcan.2016.01.010_bib0360","first-page":"326","article-title":"Glycosylated RGD-containing peptides: tracer for tumor targeting and angiogenesis imaging with improved biokinetics","volume":"42","author":"Haubner","year":"2001","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.lungcan.2016.01.010_bib0365","first-page":"1781","article-title":"Noninvasive imaging of alpha(v) beta3 integrin expression using 18F-labeled RGD-containing glycopeptide and positron emission tomography","volume":"61","author":"Haubner","year":"2001","journal-title":"Cancer Res."},{"key":"10.1016\/j.lungcan.2016.01.010_bib0370","doi-asserted-by":"crossref","first-page":"116","DOI":"10.2967\/jnumed.108.056077","article-title":"Use of a novel Arg-Gly-Asp radioligand 18F-AH111585, to determine changes in tumor vascularity after antitumor therapy","volume":"50","author":"Morrison","year":"2009","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.lungcan.2016.01.010_bib0375","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1007\/s11307-009-0279-z","article-title":"Dual in vivo quantification of integrin-targeted and protease-activated agents in cancer using fluorescence molecular tomography (FMT)","volume":"12","author":"Kossodo","year":"2010","journal-title":"Mol. Imaging Biol."},{"key":"10.1016\/j.lungcan.2016.01.010_bib0380","doi-asserted-by":"crossref","first-page":"8009","DOI":"10.1158\/0008-5472.CAN-04-1956","article-title":"In vivo near-infrared fluorescence imaging of integrin alphavbeta3 in brain tumor xenografts","volume":"64","author":"Chen","year":"2004","journal-title":"Cancer Res."},{"key":"10.1016\/j.lungcan.2016.01.010_bib0385","doi-asserted-by":"crossref","first-page":"116","DOI":"10.2967\/jnumed.108.056077","article-title":"Use of a novel Arg-Gly-Asp radioligand 18F-AH111585, to determine changes in tumor vascularity after antitumor therapy","volume":"50","author":"Morrison","year":"2009","journal-title":"J. Nucl. Med."},{"issue":"5","key":"10.1016\/j.lungcan.2016.01.010_bib0390","doi-asserted-by":"crossref","first-page":"691","DOI":"10.2967\/jnumed.112.113563","article-title":"First experience of 18F-alfatide in lung cancer patients using a new lyophilized kit for rapid radiofluorination","volume":"54","author":"Wan","year":"2013","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.lungcan.2016.01.010_bib0395","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1021\/bc0300403","article-title":"MicroPET and autoradiographic imaging of breast cancer alpha v-integrin expression using 18F- and 64Cu-labeled RGD peptide","volume":"15","author":"Chen","year":"2004","journal-title":"Bioconjug. Chem."},{"issue":"1","key":"10.1016\/j.lungcan.2016.01.010_bib0400","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1089\/cbr.2011.1061","article-title":"Whole-body distribution and radiation dosimetry of 68Ga-NOTA-RGD, a positron emission tomography agent for angiogenesis imaging","volume":"27","author":"Kim","year":"2012","journal-title":"Cancer Biother. Radiopharm."},{"key":"10.1016\/j.lungcan.2016.01.010_bib0405","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa061884","article-title":"Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer","volume":"355","author":"Sandler","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2016.01.010_bib0410","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1200\/JCO.2007.14.5466","article-title":"Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil","volume":"27","author":"Reck","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2016.01.010_bib0415","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1093\/annonc\/mdq020","article-title":"Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for non squamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)","volume":"21","author":"Reck","year":"2010","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2016.01.010_bib0420","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0969-8051(02)00393-1","article-title":"Tumor detection using 18F-labeled matrix metalloproteinase-2 inhibitor","volume":"30","author":"Furumoto","year":"2003","journal-title":"Nucl. Med. Biol."},{"key":"10.1016\/j.lungcan.2016.01.010_bib0425","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0969-8051(03)00111-2","article-title":"Comparative studies of potential cancer biomarkers carbon-11 labeled MMP inhibitors (S)-2-(4'-[11C]methoxybiphenyl-4-sulfonylamino)-3-methylbutyric acid and N-hydroxy-(R)-2-[[(4'-[11C]methoxyphenyl) sulfonyl]benzylamino]-3-methylbutanamide","volume":"31","author":"Zheng","year":"2004","journal-title":"Nucl. Med. Biol."},{"key":"10.1016\/j.lungcan.2016.01.010_bib0430","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1089\/cbr.2005.20.639","article-title":"Tryptophane-based biphenylsulfonamide matrix metalloproteinase inhibitors as tumor imaging agents","volume":"20","author":"Oltenfreiter","year":"2005","journal-title":"Cancer Biother. Radiopharm."},{"key":"10.1016\/j.lungcan.2016.01.010_bib0435","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/305137a0","article-title":"Dopamine visualized in the basal ganglia of living man","volume":"305","author":"Garnett","year":"1983","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.lungcan.2016.01.010_bib0440","first-page":"1180","article-title":"F-Dopa as an amino acid tracer to detect brain tumours","volume":"37","author":"Heiss","year":"1996","journal-title":"J. Nucl. Med."},{"issue":"7","key":"10.1016\/j.lungcan.2016.01.010_bib0445","first-page":"1161","article-title":"Imaging of advanced neuroendocrine tumors with (18)F-FDOPA PET","volume":"45","author":"Becherer","year":"2004","journal-title":"J. Nucl. Med."},{"issue":"9","key":"10.1016\/j.lungcan.2016.01.010_bib0450","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/S1470-2045(06)70801-4","article-title":"Staging of carcinoid tumours with 18F-DOPA PET: a prospective, diagnostic accuracy study","volume":"7","author":"Koopmans","year":"2006","journal-title":"Lancet Oncol."},{"issue":"3","key":"10.1016\/j.lungcan.2016.01.010_bib0455","doi-asserted-by":"crossref","first-page":"W217","DOI":"10.2214\/AJR.13.11733","article-title":"Molecular imaging of pulmonary nodules","volume":"202","author":"Maffione","year":"2014","journal-title":"Am. J. Roentgenol."},{"key":"10.1016\/j.lungcan.2016.01.010_bib0460","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1007\/s00259-008-0769-2","article-title":"Comparison between 68Ga-DOTA-NOC and 18FDOPA PET for the detection of gastro-enteropancreatic and lung neuro-endocrine tumours","volume":"35","author":"Ambrosini","year":"2008","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.lungcan.2016.01.010_bib0465","doi-asserted-by":"crossref","first-page":"120","DOI":"10.4103\/0019-509X.62998","article-title":"Non-FDG PET in the practice of oncology","volume":"47","author":"Caroli","year":"2010","journal-title":"Indian J. Cancer"},{"issue":"suppl. 2","key":"10.1016\/j.lungcan.2016.01.010_bib0470","doi-asserted-by":"crossref","first-page":"S51","DOI":"10.1093\/annonc\/12.suppl_2.S51","article-title":"Nuclear medicine imaging of neuroendocrine tumours","volume":"12","author":"Bombardieri","year":"2001","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2016.01.010_bib0475","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1007\/s002590100639","article-title":"Biokinetics andimaging with the somatostatin receptor PET radioligand 68 Ga-DOTATOC: preliminary data","volume":"28","author":"Hofmann","year":"2001","journal-title":"Eur. J. Nucl Med."},{"issue":"1","key":"10.1016\/j.lungcan.2016.01.010_bib0480","first-page":"61","article-title":"Biodistribution of the Ga-68 labeled somatostatin analogue DOTA-NOC in patients with neuroendocrine tumors: characterization of uptake in normal organs and tumor lesions","volume":"54","author":"Prasad","year":"2010","journal-title":"Q. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.lungcan.2016.01.010_bib0485","first-page":"172S","article-title":"68 Ga-labeled peptides in tumor imaging","volume":"46","author":"Maecke","year":"2005","journal-title":"J Nucl Med"},{"key":"10.1016\/j.lungcan.2016.01.010_bib0490","first-page":"109s","article-title":"Receptor PET\/CT imaging of neuroendocrine tumors using the Ga-68 labelled, high affinity somatostatin analogue DOTA-1-NaI3-octreotide (DOTA-NOC): clinical results in 327 patients","volume":"32","author":"Baum","year":"2005","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.lungcan.2016.01.010_bib0495","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s00259-009-1205-y","article-title":"Detection of unknown primary neuroendocrine tumours (CUP-NET) using (68)Ga-DOTA-NOC receptor PET\/CT","volume":"37","author":"Prasad","year":"2010","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.lungcan.2016.01.010_bib0500","doi-asserted-by":"crossref","first-page":"508","DOI":"10.2967\/jnumed.106.035667","article-title":"68Ga-DOTATyr3-octreotide PET in neuroendocrine tumours: comparison with somatostatin receptor scintigraphy and CT","volume":"48","author":"Gabriel","year":"2007","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.lungcan.2016.01.010_bib0505","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1007\/s00259-009-1349-9","article-title":"68Ga-DOTANOCPET\/CT in comparison with CT for the detection of bone metastasis in patients with neuroendocrine tumours","volume":"37","author":"Ambrosini","year":"2010","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"10","key":"10.1016\/j.lungcan.2016.01.010_bib0510","first-page":"162040","article-title":"TNM staging of NSCLC: comparison of PET\/MR and PET\/CT","volume":"56","author":"Huellner","year":"2015","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.lungcan.2016.01.010_bib0515","doi-asserted-by":"crossref","first-page":"373","DOI":"10.2967\/jnumed.113.129825","article-title":"Thoracic staging in lung cancer: prospective comparison of 18F-FDG PET\/MR imaging and 18F-FDG PET\/CT","volume":"55","author":"Heusch","year":"2014","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.lungcan.2016.01.010_bib0520","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s00259-014-2873-9","article-title":"Non-small-cell lung cancer resectability: diagnostic value of PET\/MR","volume":"42","author":"Fraioli","year":"2015","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500216300101?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500216300101?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,3]],"date-time":"2019-09-03T22:03:01Z","timestamp":1567548181000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500216300101"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4]]},"references-count":104,"alternative-id":["S0169500216300101"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2016.01.010","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2016,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The role of new PET tracers for lung cancer","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2016.01.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}